2/5 Which aspects of this site were the main reasons for the score you provided? Please select all that apply.
3/5 Which aspects of this site do you want to see changes and/or improvements to? Please select all that apply.
4/5 Did you learn anything new about the following topics on this site that you are likely to apply to your clinical practice? Please select all that apply.
5/5 Which of the following best represents your health care discipline?
Thank you!
Your feedback is invaluable and will help us improve the Halls of Science and Innovation.
You are now leaving the Novartis Halls of Science and Innovation.
This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions in that website.
IgAN is an autoimmune glomerulonephritis with heterogeneous clinical presentation, variable disease progression, and multiple underlying mechanisms.1-6 Learn more about its burden of disease and pathogenesis below.
IgAN is the most common form of primary glomerulonephritis worldwide and the leading cause of kidney failure in young White adults in the United States.1,2 IgAN incidence is higher in children and young adults (aged 20-30 years) than in older adults (aged >65 years) and is unequally distributed between sexes worldwide.1,3 In Europe and the United States, IgAN affects males more often than females (3:1), whereas IgAN is more evenly distributed between sexes in east Asia (1:1).3
Which of the following statements is false regarding IgAN?
To learn more, choose the answer that you find the most likely:
Immune complex formation and activation of the alternative, and sometimes lectin, complement pathway contribute to glomerular injury in IgAN.1,2 Diagnosis is dependent on kidney biopsy to identify IgA deposition in the glomerular mesangium and no specific, validated diagnostic laboratory tests are available.3-5 Although IgAN and IgAV (previously known as Henoch-Schönlein purpura) present with similar kidney pathology, IgAV has distinct clinical signs affecting the skin, joints, and intestines.3,5
For IgAN patients with 2 to 3 g/day proteinuria, what incidence of progression to ESKD has been observed after 5 years of follow-up?
To learn more, choose the answer that you find the most likely:
Disease progression to ESKD in patients with 2 to 3 g/day proteinuria is 20%. Proteinuria can be an important prognostic indicator in patients with IgAN. The Toronto IgAN registry followed 542 patients for 78 months; the graph demonstrates proteinuria >1 g/day is an established risk factor for poor prognosis in patients with IgAN. Renal survival with >3 g/day proteinuria is significantly worse.
Next Question Restart
References
Lai KN et al. Nat Rev Dis Primers. 2016;2:16001.
Rizk DV et al. Front Immunol. 2019;10:504.
Zand L et al. Clin Kidney J. 2023;16(2):ii19-ii27.
Karoui KE et al. J Am Soc Nephrol. 2024;35(1):103-116.
Boyd JK et al. Kidney Int. 2012;81(9):833-843.
Kohan DE et al. Kidney Int Rep. 2023;8(11):2198-2210.
Jump to topic:
Novartis Medical Information
If you require additional information or wish to contact Novartis please visit:
The Halls of Science and Innovation is a Novartis-supported educational resource, housing interactive content that provides education for health care professionals in the field of renal disease.
